secwatch.observer — SEC 8-K summary
======================================

Issuer:     Elicio Therapeutics, Inc. (ELTX)
CIK:        0001601485
Form:       8-K
Filed at:   2023-10-12T23:59:59+00:00
Accession:  0001601485-23-000062
Event type: leadership
Sentiment:  negative
Materiality: 0.55
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elicio Therapeutics terminates Chief Business Officer Annette Matthies without cause
--------------------------------------------------------------------------------

- Annette Matthies, Ph.D., Chief Business Officer, terminated without cause effective October 5, 2023.
- No replacement or interim successor named in the filing.
- Separation is effective as of the date of termination.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1601485/000160148523000062/0001601485-23-000062-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1601485/000160148523000062/angn-20231005.htm
  HTML page:      https://secwatch.observer/filing/0001601485-23-000062

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer